Join to View Full Profile
2020 Santa Monica BlvdSte 600Santa Monica, CA 90404
Phone+1 310-633-8400
Fax+1 310-633-8419
Dr. Goldman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 2005 - 2008
University of California (San Francisco)Residency, Internal Medicine, 2001 - 2004
Stanford University School of MedicineClass of 2001
Certifications & Licensure
CA State Medical License 2003 - 2027
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib
- A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants Start of enrollment: 2013 Aug 01
- Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients Start of enrollment: 2013 Nov 01
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsAmivantamab in Participants With Advanced NSCLC and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study.Matthew G Krebs, Byoung Chul Cho, Sandrine Hiret, Ji-Youn Han, Ki Hyeong Lee
Journal of Thoracic Oncology. 2025-09-01 - 1 citationsFirst-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer.Timothy A Yap, Jonathan W Goldman, Shaveta Vinayak, Antoaneta Tomova, Erika Hamilton
Clinical Cancer Research. 2025-07-15 - Brief Report: The Genomic Landscape of Small Cell Lung Cancer in Never-Smoking Patients.Michael S Oh, Edward B Garon, Aaron E Lisberg, Amy L Cummings, Alex Barrett
Clinical Lung Cancer. 2025-07-01
Lectures
- A randomized phase 3 study of abemaciclib versus erlotinib in previously treated patients with stage IV NSCLC with KRAS mutation: JUNIPER.2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
- Safety and antitumor activity of durvalumab monotherapy in patients with pretreated extensive disease small-cell lung cancer (ED-SCLC).2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Press Mentions
Bispecific Fails to Show Advantage in Phase 3 EGFR-Mutated NSCLC TrialSeptember 9th, 2025- Ivonescimab Delays Lung Cancer Progression in EGFR-Mutated DiseaseSeptember 9th, 2025
- Ivonescimab Combined with Chemotherapy Enhances Progression-Free Survival in EGFR-Positive NSCLC Patients After Third-Generation EGFR-TKI TreatmentSeptember 7th, 2025
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
